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Abstract
Background: Core biopsy is a method of choice for the triple assessment of breast disease as it
can reliably distinguish between benign and malignant tumours, between in-situ and invasive cancers
and can be useful to assess oestrogen receptor status. This study was carried out to assess the
reliability of core biopsy in predicting the grade and type of cancer accurately as obtaining this
information can influence initial therapeutic decisions.
Patients and methods: A total of 105 patients who had invasive breast carcinoma diagnosed by
core biopsy in year 2001 and who subsequently underwent surgical management were included.
The core biopsy results were compared with final histology with the help of kappa statastics.
Results: A moderate level of agreement between the predicted grades and final grades was noted
(kappa = 0.585). The agreement was good between predicted and final type of tumour (kappa =
0.639).
Conclusions: Core biopsy as a predictor of grade and type has limited use at present. We suggest
that initial clinical decisions should not be based on the results of core biopsy.
Background
Core biopsy is rapidly replacing fine needle aspiration
cytology (FNAC) as a procedure of choice for the triple
assessment of the breast problems. Where there is access
to an experienced cytopathologist, the FNAC can provide
a rapid and cost effective means of triage of patients who
would benefit from more expensive core biopsy [1]. Core
biopsy is, however, more reliable predictor of the pathol-
ogy [2-4] and can distinguish between benign and malig-
nant tumours and between in-situ and invasive cancers.
Collins et al have shown that majority (83%) of core biop-
sies and excisional procedures demonstrate exact histo-
logical agreement [5]. Core biopsy may give a good guide
to grade and type of the cancer and it can also be used to
assess the oestrogen receptor (ER) status. Core biopsy has
also been found to be a good tool to assess effect of neo-
adjuvant chemotherapy on the grade of breast cancer [6].
As the range of options for the treatment of the breast can-
cer widens, it has become increasingly important that cli-
nicians are provided with accurate prognostic information
to base the initial therapeutic decisions on. Prognostic fac-
tors for breast cancer have been extensively studied. His-
tological grade and type can be used to predict biological
behaviour as has been assessed by overall survival and
local recurrence for women with primary breast
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carcinoma [7-9]. Histological grade is one of the three
prognostic factors used in calculating the Nottingham
Prognostic Index [10].
The aim of this study, therefore, was to see how reliable
core biopsy is in predicting the grade and the type of can-
cers, as that could influence the further management of
breast cancer.
Patients and methods
All patients with invasive breast cancer diagnosed by the
core biopsy and treated subsequently by surgical excision
in the year 2001, at a district general hospital were
included in the study. Of the 105 patients whose records
were studied retrospectively, 47 lesions were palpable and
58 lesions were screen detected. The core biopsies were
performed under ultrasound guidance as a part of triple
assessment and at least four cores were obtained from pal-
pable lesions and six or more from screen detected lesions
with a 22 mm automated core biopsy gun. Two dedicated
breast pathologists had authorised all the reports. Age of
patients ranged from 35 to 84 with a median age of 62
years. The histology reports for the core biopsy and final
histology were extracted and compared. Carcinoma in-situ
diagnosed by core biopsy and patients who underwent
neo-adjuvant therapy were excluded from the study. Level
of agreement between core and excision biopsy was
assessed using kappa statistics.
Results
Of 105 patients there was no prediction of grade in 2
patients and in 19, a prediction of grade 1 or 2 or grade 2
or 3 was made. This left 84 where a clear prediction was
made. On final histology 35 (33.3%) were categorised as
grade I, 45 (42.8%) were grade II and 25 (23.8%) were
grade III. The predicted grades versus final grade results
are detailed in table 1.
Of the 84 cores in which clear prediction of grade was
made 63 (75%) were correct. All 21 of grade 1's were pre-
dicted correctly, 35 (71%) of grade 2's were predicted cor-
rectly but only 7 (50%) or grade 3's were predicted
correctly on core biopsy. Of the predicted grade 2's which
were reclassified, 5 (10%) were downgraded and 9 (18%)
were upgraded. Of the reclassified grade 3's, 6 (43%) were
downgraded to grade 2 and 1 (7%) was downgraded to
grade 1.
Of 105 patients, 101 patients had a prediction of type
made. Of 84 cases predicted to be ductal, 81 (96%) were
correct and one case was reclassified as mixed histology.
Of the 14 predicted to be lobular 9 (64%) were correct
and one reclassified as mixed (Table 2). Of the three cases
predicted as mixed only one was mixed on final
pathology.
In general the level of agreement between the predicted
grades and final grades was moderate (kappa = 0.585) and
between predicted and final types was slightly better
(kappa = 0.639).
Discussion
Fajardo et al reported percutaneous, image guided biopsy
to be an accurate diagnostic alternative to surgical biopsy
in women with mammographically detected suspicious
breast lesions [11]. The false negative results occur to a
lesser degree with image guided core biopsy [12]. How-
ever needle size [13] or amount of clinical material
obtained [14] has not been found to influence the histol-
ogy results. A recent study has shown that access to expert
breast pathologists can avoid inconsistencies observed in
the category of borderline lesions between the expert and
general pathologists [15].
Histological grade and type, tumour size and presence or
absence of axillary node metastases is well-recognised
prognostic factors of breast cancer. Tumour grade, size
and nodal involvement are three factors considered in
Nottingham Prognostic Index [10]. Histological grade
and type on their own can be helpful in predicting the bio-
logical behaviour of the tumour as regards to local recur-
rence and overall survival [7-9]. Preoperative grading and
typing with core biopsy, therefore, can influence further
Table 1: Cross tabulation showing predicted verses final grade
Final grade
Grade 1 2 3
Predicted grade 1 21 0 0
2 53 5 9
3 167
1 or 2 711
2 or 3 028
Not predicted 110
Kappa = 0.585
Table 2: Cross tabulation of predicted verses final tumour types.
Final type
Type Lobular Ductal Ducto-lobular
Predicted type Lobular 94 1
Ductal 28 1 1
Ducto-lobular 11 1
Uncertain 12 1
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management of the cancer this is all the more important
as the sensitivity and specificity of mammogram for pre-
dicting grade or type is poor [16].
Green Hough (1925) was the first to categorise the breast
tumours into three grades according to its differentiation.
He also assessed the association of grades with "cure"
though the term cure was not clearly defined [17]. Since
then a clear association between grades and prognosis has
been established [17-23]. Higher the grade, greater is the
chance of the tumour relapsing [24,25]. It has also been
noted that oestrogen receptor (ER) negative tumours are
usually of higher grade [26-28]. Higher the tumour grade
more aggressive is the tumour and nodal involvement too
is directly related to aggressiveness of the tumour [29]. All
these factors suggest that higher the grade of tumour more
radically should it be managed. Knowing the grade accu-
rately, preoperatively, would help in planning out further
management of the tumour. It is possible to identify all
these prognostic factor in core biopsy. A small earlier
study has shown 80% sensitivity of core biopsy for correct
diagnosis and a poor (50%) sensitivity for diagnosing
invasive cancers in mammographically detected cancers
[30]. It is not possible to comment on this in present
study as only invasive cancers were included in the present
study.
Of the two major histological types, lobular is known for
its multifocality and multicentricity and its diffusely infil-
trating nature [31]. It is important to correctly identify
lobular carcinoma, as these tumours are often hormone
responsive [21].
Our results suggest that the prediction of grade and type
of breast cancer from core biopsy has only limited use at
present. The group of patients we would like to be pre-
dicted most accurately would have been those with a
high-grade and lobular type, for the reasons stated above.
Our results suggest that these patients are most difficult to
predict in practice. However, present study being retro-
spective has its own drawbacks. A prospective study spe-
cifically aimed at Kappa statistics between core biopsy and
final histopathology may be able to answer this question
better. Further refinements are needed in technique of
core biopsy and these technical innovations will ulti-
mately improve the results of core biopsy.
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